Clinical Trial

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Study acronym: PNOC029
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The current study assesses the tolerability and efficacy of monotherapy with pan-RAF-kinase (Tovorafenib) inhibition for the treatment of children and young adults with craniopharyngioma.
Protocol Amendment History 28 amendments
This ClinicalTrials.gov record has been amended 28 times since 2022-07-15; most recent amendment 2026-04-21.
Status change: Not Yet Recruiting → Recruiting 2022-09-12
Trial Details
NCT Number NCT05465174
Lead Sponsor Sabine Mueller, MD, PhD
Collaborators: Day One Biopharmaceuticals, Inc.
Conditions Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Enrollment 57 participants
Start Date 2022-09-12
Primary Completion 2027-03-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23